The Problem with Coronary Stents
Coronary artery disease (CAD) is the major cause of death in the world. Plaque accumulation in the coronary artery leads to reduced blood flow and oxygen to the heart. In consequence, death of cardiac tissue may occur resulting in a heart attack.
Most CAD patients undergo artery angioplasty and stenting in order to avoid invasive and costly open-heart surgery. In North America today, stents are available as either as bare metal (BM) or coated with a particular drug (usually an anti-proliferative drug), known as Drug-Eluting Stents (DES). The DES currently dominate the market. Recently, bioresorbable stents have been developed, but recent data suggests that they are as problematic as metal stents.
On deployment, coronary stents can damage (cause a wound) to the inner lining (endothelium) of the blood vessel. This wound damage can lead to serious complications, including, in-stent re-stenosis and late-stent thrombosis.
DES are designed to only REACT to the consequences of endothelial cell damage – DESs NOT FIX THE UNDERLYING WOUND TO THE INNER LINING OF THE BLOOD VESSEL.
There is a need to design and develop new stents that repair the endothelium after stent deployment. This will improve patient outcomes, safety and reduce the economic burden on our healthcare system.
MangoGen's Solution - A Gene-Delivering Stent (GeDS)
MangoGen’s patent technology is the next generation of stent – a gene-delivering stent. On deployment, the stent coating degrades releasing baculovirus that enter the local cells around the stent. The human gene is then expressed, and an active growth factor is released that promotes the re-growth of the endothelium.